Increased fibroblast growth factor 21 is associated with metabolic syndrome in chronic spinal cord injury: A cross-sectional study
Open Access
- 2 March 2026
- journal article
- research article
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- p. 1-9
Abstract
Currently, cardiovascular disease (CVD) is the most common cause of death in people with chronic spinal cord injury (SCI) (1). When compared with the age-matched general population, people with chr...Keywords
This publication has 31 references indexed in Scilit:
- Cardiometabolic Disease and Dysfunction Following Spinal Cord InjuryPhysical Medicine and Rehabilitation Clinics of North America, 2020
- Combined exercise and calorie restriction therapies restore contractile and mitochondrial functions in skeletal muscle of obese–insulin resistant ratsNutrition, 2019
- Fibroblast growth factor-21 levels in metabolic syndrome: Another instrument in a widening tool belt?Atherosclerosis, 2019
- Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of AtherosclerosisAtherosclerosis, 2019
- Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysisMetabolism, 2018
- Factors associated with cognitive impairment in elderly versus nonelderly patients with metabolic syndrome: the different roles of FGF21Scientific Reports, 2018
- Plasma adiponectin levels are correlated with body composition, metabolic profiles, and mitochondrial markers in individuals with chronic spinal cord injurySpinal Cord, 2018
- Fasting Serum Levels of Adiponectin, Ghrelin, and Leptin in Men With Spinal Cord InjuryArchives of Physical Medicine and Rehabilitation, 2005
- Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetesDiabetologia, 2004
- Power and sample size calculationsControlled Clinical Trials, 1990